Recent Company News

• 07:36 PM ET Aug 24, 2026
  

  Astellas Pharma doses first patient in Phase 3 ASP2138 study to treat CLDN18.2-positive gastric, GEJ adenocarcinoma (¥2406.5000, 0)

• 12:40 AM ET Aug 18, 2026
  

  Astellas Pharma initiated outperform at CLSA (¥2290.5000, +7.5)

• 10:55 PM ET Aug 05, 2026
  

  Quick Take - Astellas Pharma trading +4.8% on strong Q1 beat (¥2262.5000, +103.5)

• 01:05 PM ET Aug 05, 2026
  

  Transcript Intelligence: Astellas Pharma Q1 Earnings Guidance

• 01:05 PM ET Aug 05, 2026
  

  Transcript Intelligence: Astellas Pharma Q1 Earnings Themes

• 01:05 PM ET Aug 05, 2026
  

  Transcript Intelligence: Astellas Pharma Q1 Earnings Q&A

• 02:40 AM ET Aug 05, 2026
  

  Astellas Pharma reports Q1 core net income ¥170.50B vs FactSet ¥137.37B (¥2159.0000, 0)

• 05:50 PM ET Jul 28, 2026
  

  Astellas Pharma initiated neutral at SBI Securities Japan (¥2233.5000, 0)

• 04:33 PM ET Jul 22, 2026
  

  FDA grants Priority Review for Pfizer's sNDA for TALZENNA + XTANDI in metastatic prostate cancer; PDUFA date in last quarter of 2026 ($24.82, 0.00)

• 07:08 PM ET Jul 21, 2026
  

  President Trump states tariff on generic drugs will stay at 0% for 2 years then rise to 100% - Truth Social